You are here

Safety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail

Last updated on December 16, 2017

FOR MORE INFORMATION
Study Location
Instituto Dermatologico Jalisciense
Guadalajara, , Mexico
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Onychomycosis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Subjects must meet all of the following criteria to be included in the study:

2. Witnessed, signed informed consent approved by Ethics Committee.

3. Male or female subjects of any race at least 18 years of age but not older than 65
years of age at the time of screening.

4. For Cohorts 1 and 2, subjects with a diagnosis of onychomycosis of at least one great
toenail and with a positive KOH wet mount from that nail. For Cohort 3, subjects must
have a diagnosis of onychomycosis of at least one great toenail and a positive KOH wet
mount AND fungal culture from that nail.

5. Onychomycosis involving 20-60% of the affected great toenail as determined by visual
inspection after the nail has been trimmed.

6. The combined thickness of the distal nail plate and the associated hyperkeratotic nail
bed

7. Affected great toenail to be treated is capable of re-growth as documented by history
or recent observation of at least 2 mm of growth.

8. Normal or not clinically significant screening safety labs.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

1. Females of childbearing potential not using a highly effective method of birth control
(e.g. implants, injectables, combined oral contraceptives, some intrauterine
contraceptive devices) during the study.

2. Diabetes mellitus requiring treatment other than diet and exercise.

3. Subjects with chronic moccasin type of T. pedis.

4. Subjects with a history of having failed any previous topical antifungal therapy for
their onychomycosis.

5. Subjects unwilling to refrain from the use of nail cosmetics such as clear and or
colored nail lacquers from the screening visit until the end of the study.

6. Subjects that have not undergone the specified washout period(s) for the following
topical preparations or subjects who require the concurrent use of any of the
following topical medications:

- Topical antifungal applied to the feet (does not include antifungals for
treatment of T. pedis during the study): 4 weeks

- Anti-inflammatories, corticosteroids, topical immunomodulators: 2 weeks

7. Subjects that have not undergone the specified washout period(s) for the following
systemic medications or subjects who require the concurrent use of any of the
following systemic medications:

- Corticosteroids (including intramuscular injections): 2 weeks

- Antifungals for treatment of onychomycosis or any systemic antifungal with known
activity against dermatophytes: 24 weeks

- Systemic immunomodulators: 4 weeks

8. Treatment of any type for cancer within the last 6 months.

9. History of any significant internal disease.

10. Subjects with a medical history of current or past psoriasis of the skin and/or nails.

11. Concurrent lichen planus.

12. Subjects who are known to be allergic to any of the test product(s) or any components
in the test product(s) or history of hypersensitivity or allergic reactions to any of
the study preparations as described in the Investigator's Brochure.

13. Nail or anatomic abnormalities of the toe, e.g., genetic nail disorders, primentary
disorders, onychogryphosis, trauma to the nail(s) to be treated.

14. AIDS or AIDS related complex.

15. History of street drug or alcohol abuse.

16. Any subject not able to meet the study attendance requirements.

17. Subjects who have participated in any other trial of an investigational drug or device
within 60 days prior to enrollment or participation in a research study concurrent
with this study.

NCT01278394
Pfizer
Completed
Safety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Safety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail
An Open-Label, Rising Multiple-Dose, Multi-Center Study to Evaluate the Safety and Efficacy of Topically Applied AN2690 5.0% and 7.5% Solution for the Treatment of Adult Subjects With Onychomycosis of the Great Toenail
The purpose of the study is to determine the safety and efficacy of 5.0% AN2690 Solution in the treatment of distal, subungual onychomycosis of the great target toenail.

In this cohort, only the targeted great toenail identified at Baseline prior to the commencement of treatment from culture results collected at the Screening visit were evaluated for primary efficacy whereas all treated toenails were evaluated for safety. At each visit, the investigator was asked to make a clinical evaluation of the targeted great nail, marking whether or not they considered the nail to be clear of onychomycosis. This evaluation was the basis for determining whether or not study medication should be dispensed at the visit.

This record includes information only for Cohort 3 (5% solution) of the study. Cohorts 1 and 2, are described in NCT00679523 (7.5% solution). No comparison was made between Cohorts 1&2 and Cohort 3.

Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Onychomycosis
Drug: AN2690 Solution, 5.0%
Once daily application for 360 days
Experimental: Group 1
AN2690 Solution, 5.0%
Intervention: Drug: AN2690 Solution, 5.0%
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
29
July 2008
July 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Subjects must meet all of the following criteria to be included in the study:
  2. Witnessed, signed informed consent approved by Ethics Committee.
  3. Male or female subjects of any race at least 18 years of age but not older than 65 years of age at the time of screening.
  4. For Cohorts 1 and 2, subjects with a diagnosis of onychomycosis of at least one great toenail and with a positive KOH wet mount from that nail. For Cohort 3, subjects must have a diagnosis of onychomycosis of at least one great toenail and a positive KOH wet mount AND fungal culture from that nail.
  5. Onychomycosis involving 20-60% of the affected great toenail as determined by visual inspection after the nail has been trimmed.
  6. The combined thickness of the distal nail plate and the associated hyperkeratotic nail bed <3 mm.
  7. Affected great toenail to be treated is capable of re-growth as documented by history or recent observation of at least 2 mm of growth.
  8. Normal or not clinically significant screening safety labs.

Exclusion Criteria:

  1. Females of childbearing potential not using a highly effective method of birth control (e.g. implants, injectables, combined oral contraceptives, some intrauterine contraceptive devices) during the study.
  2. Diabetes mellitus requiring treatment other than diet and exercise.
  3. Subjects with chronic moccasin type of T. pedis.
  4. Subjects with a history of having failed any previous topical antifungal therapy for their onychomycosis.
  5. Subjects unwilling to refrain from the use of nail cosmetics such as clear and or colored nail lacquers from the screening visit until the end of the study.
  6. Subjects that have not undergone the specified washout period(s) for the following topical preparations or subjects who require the concurrent use of any of the following topical medications:

    • Topical antifungal applied to the feet (does not include antifungals for treatment of T. pedis during the study): 4 weeks
    • Anti-inflammatories, corticosteroids, topical immunomodulators: 2 weeks
  7. Subjects that have not undergone the specified washout period(s) for the following systemic medications or subjects who require the concurrent use of any of the following systemic medications:

    • Corticosteroids (including intramuscular injections): 2 weeks
    • Antifungals for treatment of onychomycosis or any systemic antifungal with known activity against dermatophytes: 24 weeks
    • Systemic immunomodulators: 4 weeks
  8. Treatment of any type for cancer within the last 6 months.
  9. History of any significant internal disease.
  10. Subjects with a medical history of current or past psoriasis of the skin and/or nails.
  11. Concurrent lichen planus.
  12. Subjects who are known to be allergic to any of the test product(s) or any components in the test product(s) or history of hypersensitivity or allergic reactions to any of the study preparations as described in the Investigator's Brochure.
  13. Nail or anatomic abnormalities of the toe, e.g., genetic nail disorders, primentary disorders, onychogryphosis, trauma to the nail(s) to be treated.
  14. AIDS or AIDS related complex.
  15. History of street drug or alcohol abuse.
  16. Any subject not able to meet the study attendance requirements.
  17. Subjects who have participated in any other trial of an investigational drug or device within 60 days prior to enrollment or participation in a research study concurrent with this study.
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Mexico
 
 
NCT01278394
AN2690-ONYC-201 Cohort 3
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Karl Beutner, MD, PhD Pfizer
Pfizer
September 2017

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now